New study tracks eylea safety in preemie eyes
NCT ID NCT05705258
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study watches Japanese babies with retinopathy of prematurity (ROP) who are already getting Eylea eye injections. Researchers will track side effects and check if the treatment stops active ROP for up to 6 months. No extra tests are done—just routine care data is collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Many locations
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.